Today's Daily Dose brings you news about Neurocrine Biosciences' upcoming regulatory catalyst; Celgene's RADIANCE Part B trial results; tentative approval of Eagle Pharma's cancer drug Pemfexy; trial results of Kura's preclinical drug candidate, KO-539, and phase II drug candidate Tipifarnib.
from RTT - Biotech http://ift.tt/2ifMTd5
via IFTTT
No comments:
Post a Comment